CDSCO clears recombinant live attenuated dengue vaccine for ages 4 to 60 years
India has approved its first dengue vaccine, with the Central Drugs Standard Control Organisation (CDSCO) granting marketing authorisation for the Dengue Tetravalent Vaccine (Live, Attenuated) – Qdenga. Manufactured by Takeda GmbH, Germany, the vaccine will be imported by Takeda Biopharmaceuticals India Pvt. Ltd.The vaccine is indicated for the prevention of dengue in individuals 4 to 60 years of age.
- ▪India has approved its first dengue vaccine, with the Central Drugs Standard Control Organisation (CDSCO) granting marketing authorisation for the Dengue Tetravalent Vaccine (Live, Attenuated) – Qdenga.
- ▪Manufactured by Takeda GmbH, Germany, the vaccine will be imported by Takeda Biopharmaceuticals India Pvt.
- ▪Ltd.The vaccine is indicated for the prevention of dengue in individuals 4 to 60 years of age.
Opening excerpt (first ~120 words) tap to expand
India has approved its first dengue vaccine, with the Central Drugs Standard Control Organisation (CDSCO) granting marketing authorisation for the Dengue Tetravalent Vaccine (Live, Attenuated) – Qdenga. Manufactured by Takeda GmbH, Germany, the vaccine will be imported by Takeda Biopharmaceuticals India Pvt. Ltd.The vaccine is indicated for the prevention of dengue in individuals 4 to 60 years of age. “The approval has been granted after a comprehensive scientific evaluation of the vaccine’s quality, safety and efficacy in accordance with the provisions of the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945,” said a statement issued by the Union Health Ministry on Tuesday (July 21, 2026).What is Qdenga?Qdenga is a live, attenuated tetravalent dengue vaccine developed using…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Hindu — Top.
Discussion
0 commentsMore from The Hindu — Top
